


Biosimilars clinical development gains momentum in 2025

Market Trend Summary

Clinical development of biosimilars: a global perspective

With over 700 biosimilars currently in development globally, China, followed by Russia and India, leads the way in terms of the highest number of biosimilars in the clinical phase of development.




64
 BIOSIMILAR BRANDS LAUNCHED IN THE UNITED STATES, referencing
39 REFERENCE BRANDS

74
 BIOSIMILAR BRANDS LAUNCHED IN EUROPE, referencing
49 REFERENCE BRANDS

>700
 BIOSIMILARS IN DEVELOPMENT GLOBALLY

2025 began with approvals and partnerships propelling biosimilars

Biosimilar approvals and launches—especially for ustekinumab and denosumab—increased in 2025 compared with 2024, driving growth in the biosimilars market.



About the author



Yashu Malhotra, M. Pharm.

**Senior Healthcare Research and Data Analyst,
Biosimilars**

Yashu Malhotra, M. Pharm., is senior analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master's degree in pharmacy (quality assurance) from India's Delhi Institute of Pharmaceutical Sciences and Research.

Yashu.Malhotra@Clarivate.com

Clarivate coverage of Biosimilars

- [Biosimilars | Market Events and Forecast | G7](#)
- [Biosimilars | Emerging Biosimilars | Global](#)
- [Biosimilars | Access & Reimbursement | Payer Insights | US/EU](#)
- [Biosimilars | Access & Reimbursement | Global Landscape](#)
- [Biosimilars | Corporate Strategies | Global](#)
- [Biosimilars | China-in Depth | China](#)



Think forward™

Have a question?

healthcare.support@clarivate.com
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://www.clarivate.com)

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.